This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Frank Powers, Jr
Branch Manager Shearson Lehman Hutton Tampa, Fla

JAMA. 1990;264(3):334.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

I'm sorry if there was any misunderstanding about the nature of the call my colleague made to Dr Morris. The call was intended specifically to discuss investment opportunities in the biotechnology industry.

Our equity research analysts who follow the pharmaceutical and biotechnology industries are among the most highly regarded in the securities industry. Shearson believes that there are many companies that represent attractive investment opportunities in these areas, particularly those distributing erythropoietin.

Shearson Lehman Hutton is not aware of any restrictions that preclude physicians from investing in pharmaceutical companies while they prescribe those companies' products. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?